WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017183673) ANTI-CANCER DRUG ASSESSMENT METHOD
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/183673 International Application No.: PCT/JP2017/015804
Publication Date: 26.10.2017 International Filing Date: 19.04.2017
IPC:
C12Q 1/02 (2006.01)
Applicants: TOPPAN PRINTING CO., LTD.[JP/JP]; 5-1, Taito 1-chome, Taito-ku, Tokyo 1100016, JP
Inventors: KITANO Shiro; JP
TSUKAMOTO Kei; JP
IRIE Shinji; JP
Agent: SUZUKI Shirou; JP
SHIGA Masatake; JP
TAKAHASHI Norio; JP
FUSHIMI Shunsuke; JP
Priority Data:
2016-08394819.04.2016JP
2016-08395019.04.2016JP
2016-08395119.04.2016JP
Title (EN) ANTI-CANCER DRUG ASSESSMENT METHOD
(FR) PROCÉDÉ D’ÉVALUATION DE MÉDICAMENT ANTICANCÉREUX
(JA) 抗がん剤の評価方法
Abstract:
(EN) This anti-cancer drug assessment method involves: a culturing step for culturing a cell structure containing cells which constitute cancer cells and stromal tissue while in the presence of one or more types of anti-cancer drug; and an assessment step for assessing the anti-cancer effect of the anti-cancer drug, with the indicator thereof being the viable cell count of the cancer cells in the cell structure following the culturing step.
(FR) L’invention concerne un procédé d’évaluation de médicament anticancéreux, comprenant : une étape de culture consistant à mettre en culture une structure cellulaire contenant des cellules qui constituent des cellules cancéreuses et du tissu stromal en présence d’un ou plusieurs types de médicament anticancéreux ; et une étape d’évaluation consistant à évaluer l’effet anticancéreux du médicament anticancéreux, son indicateur étant la numération de cellules viables des cellules cancéreuses dans la structure cellulaire après l’étape de culture.
(JA) 抗がん剤の評価方法は、がん細胞及び間質を構成する細胞を含む細胞構造体を、1種又は2種以上の抗がん剤の存在下で培養する培養工程と、前記培養工程後の前記細胞構造体中のがん細胞の生細胞数を指標として、前記抗がん剤の抗がん効果を評価する評価工程と、を有する。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)